TOP STORIES

• REGULATORY Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
  April 28, 2022

• REGULATORY Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
  April 28, 2022

• ORGANIZATION JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
  April 27, 2022

• BUSINESS Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
  April 27, 2022

• BUSINESS Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
  April 26, 2022

• BUSINESS Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
  April 26, 2022

• REGULATORY Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
  April 26, 2022

• REGULATORY SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
  April 25, 2022

• BUSINESS MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
  April 22, 2022

• BUSINESS GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
  April 21, 2022

• BUSINESS Lumakras, Bimzelx, Pivlaz Now Available in Japan
  April 21, 2022

• BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
  April 20, 2022

• REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
  April 19, 2022

• REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
  April 19, 2022

• REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
  April 19, 2022

• COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
  April 19, 2022

• REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
  April 18, 2022

• BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
  April 15, 2022

• BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
  April 14, 2022

• REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
  April 13, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 73
• 74
• 75
• 76
• 77
• 78
• 79
• 80
• 81
• …
• Next ›
• 最終 »